Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …

Background The poly (adenosine diphosphate–ribose) inhibitor talazoparib has shown
antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 …

Triple-negative breast cancer is a heterogeneous disease and specific therapies have not
been available for a long time. Therefore, conventional chemotherapy is still considered the …

Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are
often aggressive and associated with a poor prognosis. Molecular characterization, while …

Purpose One third of patients with triple-negative breast cancer (TNBC) achieve pathologic
complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 …

Activation of checkpoint arrest and homologous DNA repair are necessary for maintenance
of genomic integrity during DNA replication. Germ-line mutations of the ataxia telangiectasia …

Carcinogenesis is a multistep process, and tumors frequently harbor multiple mutations
regulating genome integrity, cell division and death. The integrity of cellular genome is …

Triple-negative breast cancer (TNBC) is characterised by poor outcomes and a historical
lack of targeted therapies. Dysregulation of signalling through the phosphoinositide 3 (PI3) …

Genes in which germline mutations confer highly or moderately increased risks of cancer
are called cancer predisposition genes. More than 100 of these genes have been identified …